Literature DB >> 26390942

Abrogation of AuroraA-TPX2 by novel natural inhibitors: molecular dynamics-based mechanistic analysis.

Ankita Gupta1, Ritu Jain2, Divya Wahi2, Sukriti Goyal2, Salma Jamal2, Abhinav Grover2.   

Abstract

INTRODUCTION: Cancer is characterized by uncontrolled cell growth and genetic instabilities. The human Aurora-A kinase protein plays a crucial role in spindle assembly during mitosis and is activated by another candidate oncogene, targeting protein for Xklp2 (TPX2). It has been proposed that dissociation of Aurora A-TPX2 complex leads to disruption of mitotic spindle apparatus, thereby preventing cell division and further tumor growth.
MATERIALS AND METHODS: A large natural compound library was docked against the active site of Aurora A-TPX2 complex. The protein-ligand complexes were subjected to molecular dynamics simulation to ascertain their binding stability. The drug properties of the compounds were analyzed to observe their drug-like properties.
RESULTS: The virtual screening of natural compound library yielded two high scoring compounds, the first compound CTOM [ZINC ID: 38143674] (Glide score: -9.49) was stable for 17 ns while the second TTOM (Glide score: -9.07) was stable for 15 ns. While CTOM interacted with His280, Thr288 of Aurora A and Tyr34, Lys38 of TPX2, TTOM interacted with Arg285 and Arg286 in addition to the residues involved with CTOM.
CONCLUSIONS: We report two natural compounds as potential drugs leads for the disruption of this complex. These ligands show a preferable docking score and have many drugs like properties within in the range of 95% of known drugs. The study provides evidence that CTOM and TTOM can efficiently inhibit the TPX2-mediated activation of Aurora A. Thus, it paves way for an elaborate investigation and establishes the importance of computational approaches as time- and cost-effective techniques.

Entities:  

Keywords:  Aurora A; TPX2; cancer; inhibitors; molecular dynamics; natural; simulations

Mesh:

Substances:

Year:  2015        PMID: 26390942     DOI: 10.3109/10799893.2015.1041645

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  4 in total

1.  RNF181 modulates Hippo signaling and triple negative breast cancer progression.

Authors:  Rui Zhou; Yinlu Ding; Min Xue; Bin Xiong; Ting Zhuang
Journal:  Cancer Cell Int       Date:  2020-07-06       Impact factor: 5.722

2.  Novel group-based QSAR and combinatorial design of CK-1δ inhibitors as neuroprotective agents.

Authors:  Kopal Joshi; Sukriti Goyal; Sonam Grover; Salma Jamal; Aditi Singh; Pawan Dhar; Abhinav Grover
Journal:  BMC Bioinformatics       Date:  2016-12-22       Impact factor: 3.169

3.  The critical role of dysregulated Hh-FOXM1-TPX2 signaling in human hepatocellular carcinoma cell proliferation.

Authors:  Yiting Wang; Hailong Wang; Zhengwei Yan; Guohua Li; Guohui Hu; Hong Zhang; Dengliang Huang; Yao Wang; Xiang Zhang; Yehong Yan; Quqin Lu; Minzhang Cheng; Shiwen Luo
Journal:  Cell Commun Signal       Date:  2020-07-28       Impact factor: 5.712

4.  Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.

Authors:  Sharad Verma; Sukriti Goyal; Anchala Kumari; Aditi Singh; Salma Jamal; Abhinav Grover
Journal:  PLoS One       Date:  2018-02-01       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.